Inspire Medical Systems, Inc. (INSP)
NYSEHealth CareMedical - DevicesSnapshot 2026-10-29
$68.10-4.33%
Close 2026-10-30 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-10-29
Research Workspace
Put INSP beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Maintain adjusted operating margin between 2% and 4% in 2026: Direct metric needs a verified mapping.
View ThesisRevenue growth is slowing — up about 4% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 15%.
View QualityManagement screens strong on earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 72% in its worst 12-month stretch.
View RiskInspire Medical’s case rests on resolving Inspire V reimbursement uncertainty through new CPT codes. Recent results remain strong by the desk’s assessment, though revenue growth turned negative in Q2 FY2026. INSP reported a non-GAAP earnings beat in Q2 FY2026. Revenue fell 7.6% year over year that quarter. INSP trades at 31× P/E versus a 30× peer median. The desk says the price reflects less growth than its forecast. The specific risk is pressure on the 2026 adjusted operating margin target, whose metric mapping needs verification. Our model puts the next-quarter miss probability near 12%. Peer multiples imply a price roughly in line with where it trades (about fair). The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-30. INSP is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering INSP (as of Oct 2026).
Based on 10 Wall Street analysts offering 12-month price targets for INSP in the last 4 months.
Continue this research
Compare INSP with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| INSP Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put INSP next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Resolve coding and reimbursement uncertainty for Inspire V
New CPT codes enhance reimbursement clarity for Inspire V.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $68.10
The last 12 months of price, then the range of analyst 12-month targets from today’s $68.10.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
